Maryland's Medical Marijuana Industry to be Regulated by Alcohol and Tobacco Commission.

Dec.20.2022
Maryland's Medical Marijuana Industry to be Regulated by Alcohol and Tobacco Commission.
Maryland MMJ industry oversight to be transferred to state's alcohol and tobacco commission starting 2023. Adult-use sales legalized.

Beginning in 2023, the medical marijuana industry in Maryland, United States, will be regulated by the state's alcohol and tobacco commission.


The Marijuana Medical Commission of Maryland (MMCC) has been overseeing the state's medical marijuana industry since sales began in December 2017.


During the midterm elections in November, the situation changed as Maryland voters decided to legalize the sale of marijuana for adult use.


According to a press release from MMCC, the regulation of medical marijuana will transition from the Medical Marijuana Commission to the Alcohol and Tobacco Commission in 2023, as mandated by a law passed by voters.


According to an announcement, Chairperson Tiffany Randolph will step down on December 31st.


In the past five years, commission members and staff have established Maryland as a model for medical marijuana programs and have helped the state prepare for the transition to an expanded medical and adult-use market," said Randolph in a statement.


According to a press release, Dr. C. Obi Onyewu, current Vice-Chair of MMCC, will serve as acting Chair as Maryland launches a recreational marijuana market.


Starting from July 1, 2023, it will be legal for adults aged 21 and above to consume and possess up to 1.5 ounces of marijuana.


The true retail market may not begin until 2024 or 2025.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

BAT says a U.S. import block on some disposable vapes could cut illegal sales by about a third
BAT says a U.S. import block on some disposable vapes could cut illegal sales by about a third
Reuters reported that British American Tobacco (BAT) CEO Tadeu Marroco said a potential U.S. move to block imports of some disposable vapes could reduce the market for unregulated e-cigarettes by as much as a third, though any impact is unlikely before 2027.
Feb.13 by 2FIRSTS.ai
German Environment Minister Backs Ban on Disposable E-Cigarettes, Citing Safety Risks
German Environment Minister Backs Ban on Disposable E-Cigarettes, Citing Safety Risks
Germany’s Environment Minister Carsten Schneider has expressed clear support for banning disposable e-cigarettes, citing safety hazards, environmental damage, and waste management risks. While the ban has not yet been finalized, Germany’s parliament has instructed the government to examine the proposal. Several European countries, including Belgium, France, and the UK, have already implemented similar bans.
Dec.30 by 2FIRSTS.ai
Product | ON! PLUS: Breakdown of Six FDA-PMTA-Authorized Nicotine Pouches—6/9 mg Strengths, Slim Format, and Traditional Flavours
Product | ON! PLUS: Breakdown of Six FDA-PMTA-Authorized Nicotine Pouches—6/9 mg Strengths, Slim Format, and Traditional Flavours
The U.S. FDA has added six ON!® PLUS nicotine pouch products to its list of Marketing Granted Order (MGO) authorizations. Based on 2Firsts’ review, the approved products feature a highly standardized configuration in terms of format, nicotine strength, and flavour portfolio, primarily focusing on 6 mg and 9 mg strengths and traditional variants such as mint, wintergreen, and tobacco—reflecting a clear compliance-oriented approach.
Dec.22 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11
Consultation opens for Tasmania’s Public Health Amendment Bill 2026
Consultation opens for Tasmania’s Public Health Amendment Bill 2026
Consultation opened on February 6, 2026 for the Public Health Amendment (Prohibited Tobacco and Other Products) Bill 2026. The Bill intends to address illicit trade in tobacco, nicotine pouches and e-cigarettes, which has increased significantly across Tasmania in recent years. It proposes changes to the Public Health Act 1997 to further protect the health of Tasmanians by reducing the sale and supply of illicit tobacco, vaping and other products, and to strengthen existing tobacco control laws.
Feb.06 by 2FIRSTS.ai
South Korea’s appeal court again sides with KT&G, Philip Morris Korea and BAT Korea in $36.24 million case
South Korea’s appeal court again sides with KT&G, Philip Morris Korea and BAT Korea in $36.24 million case
South Korea’s National Health Insurance Service (NHIS) has again lost on appeal in its damages lawsuit against KT&G, Philip Morris Korea and BAT Korea, seeking ₩53.3 billion (about $36.244 million).
Jan.15 by 2FIRSTS.ai